Related Experiment Video
Updated: May 9, 2025

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
Published on: July 12, 2022
Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers
Soniya Abraham1, Jay Parekh1, Seohyuk Lee2
1Department of Internal Medicine, Yale-New Haven Health Bridgeport Hospital, Bridgeport, Connecticut, USA.
Background:
Aging in humans is a heterogeneous process influenced by both biological and chronological factors. Biological age reflects an individual's physiological reserve and functional status. Increasing evidence suggests that cancer and its therapies accelerate biological aging. Many biomarkers have been evaluated to assess the biological age of patients with cancer. These biomarkers are emerging as potential tools to predict cancer-related toxicity and an individual's functional capacity as well as to individualize treatment.
Methods:
This review summarizes the current literature on aging biomarkers in cancer patients, with a focus on markers of cellular senescence and epigenetic modification. We evaluate the existing evidence supporting their use as predictors of toxicity in patients undergoing chemotherapy and radiation therapy.
Results:
Biomarkers such as interleukin-6 (IL-6), leukocyte telomere length (LTL), and DNA methylation age show potential for assessing biological age, frailty, and functional reserve. The expression of p16INK4A has demonstrated promise in predicting therapy-induced toxicity and making treating decisions. However, additional confirmatory studies are necessary to further validate these biomarkers before they can be utilized as decision aids.
Conclusion:
Aging biomarkers hold promise for individualizing cancer therapy and predicting treatment-related toxicity. However, further studies are essential to validate their reliability and support their integration into clinical practice.
More Related Videos
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...